174003-17-9

Basic information

• Product Name: L-Tyrosine, N-[(1,1-dimethylethoxy)carbonyl]-, 1,1-dimethylethyl ester,trifluoromethanesulfonate (ester)
• Synonyms: (S)-2-tert-Butoxycarbonylamino-3-(4-trifluoromethanesulfonyloxy-phenyl)-propionic acid tert-butyl ester
• CAS NO: 174003-17-9
• Molecular Formula: C19H26F3NO7S
• Molecular Weight: 469.479
• Mol File: 174003-17-9.mol
• Article Data: 6

Chemical Properties

• CAS DataBase Reference: L-Tyrosine, N-[(1,1-dimethylethoxy)carbonyl]-, 1,1-dimethylethyl ester,trifluoromethanesulfonate (ester)(CAS DataBase Reference)
• NIST Chemistry Reference: L-Tyrosine, N-[(1,1-dimethylethoxy)carbonyl]-, 1,1-dimethylethyl ester,trifluoromethanesulfonate (ester)(174003-17-9)
• EPA Substance Registry System: L-Tyrosine, N-[(1,1-dimethylethoxy)carbonyl]-, 1,1-dimethylethyl ester,trifluoromethanesulfonate (ester)(174003-17-9)

Safety Data

• Hazardous Substances Data: 174003-17-9(Hazardous Substances Data)

Upstream product

• 358-23-6 trifluoromethylsulfonic anhydride 
• 18938-60-8 (S)-tert-butyl 2-((tert-butoxycarbonyl)amino)-3-(4-hydroxyphenyl)propanoate 
• 16874-12-7 Tyr(tBu) 
• 37595-74-7 N,N-phenylbistrifluoromethane-sulfonimide 
• 24424-99-5 di-tert-butyl dicarbonate 

Downstream Products

• 945259-94-9 tert-butyl (S)-2-((tert-butoxycarbonyl)amino)-3-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)propanoate 
• 1443792-20-8 tert-butyl (S)-3-(4-(5-bromopyrimidin-2-yl)phenyl)-2-(5-(tert-butyl)thiophene-2-carboxamido)propanoate 

Relevant articles and documents

N-aryl 2,6-dimethoxybiphenylalanine analogues as VLA-4 antagonists

A series of N-arylated phenylalanine derivatives has been synthesized and has been shown to be potent inhibitors of the integrin VLA-4. N-phenyl and N-heteroaryl derivatives with hydrogen bond acceptors in the meta position demonstrated low nanomolar acti

NOVEL GLP-1 RECEPTOR MODULATORS

Compounds are provided that modulate the glucagon-like peptide 1 (GLP-1) receptor, as well as methods of their synthesis, and methods of their therapeutic and/or prophylactic use. Such compounds can act as modulators or potentiators of GLP-1 receptor on their own, or with incretin peptides such as GLP-1(7-36), GLP-1(9-36), and oxyntomodulin, or with peptide-based therapies, such as exenatide and liraglutide, and have the following general structure (where "?" represents either or both the R and S form of the compound): where A, B, C, R1, R2, R3, R4, R5, n, p and q are as defined herein.

PPAR-γ agonists as agents for the treatment of type II diabetes

N-(substituted)carbamoylaryl- and heteroaryl substituted aminopropanoic and butanoic acid compounds which are highly selective agonists for the PPAR-γ receptor or prodrugs of agonists for the PPAR-γ receptor, and are useful in the treatment of Type II dia